Genocea's Pipeline

Genocea has applied its proprietary human antigen discovery technology to rapidly build a pipeline of therapeutic and preventative T cell vaccines for infectious diseases. In less than one year, the company has moved from program inception through antigen discovery to demonstration of preclinical proof-of-concept in three major diseases. The most advanced program is a herpes simplex virus type 2 (HSV-2) therapeutic vaccine. All of these programs are designed to yield vaccines with utility across diverse populations.